Caribou Biosciences, Inc.
CRBU
$1.86
$0.105.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.20M | 2.67M | 2.35M | 2.08M | 2.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.20M | 2.67M | 2.35M | 2.08M | 2.02M |
| Cost of Revenue | 1.21M | 1.30M | 1.74M | 29.86M | 1.64M |
| Gross Profit | 986.00K | 1.37M | 610.00K | -27.79M | 386.00K |
| SG&A Expenses | 9.20M | 10.40M | 9.74M | 10.49M | 9.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.60M | 38.10M | 45.27M | 40.35M | 40.26M |
| Operating Income | -29.40M | -35.43M | -42.91M | -38.28M | -38.24M |
| Income Before Tax | -27.55M | -54.10M | -39.99M | -35.50M | -34.68M |
| Income Tax Expenses | -- | -- | -- | -9.00K | -- |
| Earnings from Continuing Operations | -27.55M | -54.10M | -39.99M | -35.49M | -34.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.55M | -54.10M | -39.99M | -35.49M | -34.68M |
| EBIT | -29.40M | -35.43M | -42.91M | -38.28M | -38.24M |
| EBITDA | -28.77M | -34.26M | -41.75M | -37.09M | -37.06M |
| EPS Basic | -0.30 | -0.58 | -0.43 | -0.39 | -0.38 |
| Normalized Basic EPS | -0.18 | -0.28 | -0.27 | -0.24 | -0.24 |
| EPS Diluted | -0.30 | -0.58 | -0.43 | -0.39 | -0.38 |
| Normalized Diluted EPS | -0.18 | -0.28 | -0.27 | -0.24 | -0.24 |
| Average Basic Shares Outstanding | 93.29M | 93.03M | 92.68M | 91.16M | 90.46M |
| Average Diluted Shares Outstanding | 93.29M | 93.03M | 92.68M | 91.16M | 90.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |